Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis
prognosis
Lung carcinomas
non-small-cell
programmed death-ligand 1
Journal
Balkan medical journal
ISSN: 2146-3131
Titre abrégé: Balkan Med J
Pays: Turkey
ID NLM: 101571817
Informations de publication
Date de publication:
10 05 2019
10 05 2019
Historique:
entrez:
29
12
2018
pubmed:
29
12
2018
medline:
3
1
2020
Statut:
ppublish
Résumé
Prognostic significance of the programmed death-ligand-1 status in non-small cell lung carcinoma remains controversial. To show the programmed death-ligand-1 expression status in patients with non-small cell lung carcinoma and its effect on the prognosis and the relationship with clinicopathologic data. Retrospective cross-sectional study. The study included 208 cases who were diagnosed with NSCLC and who underwent surgical resection between 2001 and 2012. Programmed death-ligand-1 (SP142 clone) was applied to the histological sections acquired from the microarray paraffin blocks with immunohistochemistry. Staining intensity was scored as weak (+, 1), moderate (++, 2), and strong (+++, 3). Percentage (0%-100%) was multiplied by staining intensity (1-2-3) to calculate the H score. Four different cut-off values were used; 1: ≥1% (independent of intensity), 2: ≥5% (independent of intensity), 3: ≥5% moderate/strong staining (except for weak staining), 4: H score ≥30 values were considered positive. In this study, staining a single cell at any intensity was considered positive. Thirty-four out 208 cases (16.3%) had PDL-1 positive staining. PDL-1 expression was observed in patients with non-small cell lung carcinoma independent of the histological type or subtype (range; 0-25%). When the cut-off level was set to ≥5% with moderate and strong staining, the median overall survival was 45 months for the PD-L1 positive group and not reached for the PD-L1 negative group (p-value 0.024). PD-L1 positivity was significantly higher in patients over the age of 60 years and in cases with a tumor diameter of more than 5 cm (p=0.023 and 0.025, respectively). PD-L1 expression is positive in 16.3% of patients with non-small cell lung cancer and may have a negative prognostic value.
Sections du résumé
Background
Prognostic significance of the programmed death-ligand-1 status in non-small cell lung carcinoma remains controversial.
Aims
To show the programmed death-ligand-1 expression status in patients with non-small cell lung carcinoma and its effect on the prognosis and the relationship with clinicopathologic data.
Study Design
Retrospective cross-sectional study.
Methods
The study included 208 cases who were diagnosed with NSCLC and who underwent surgical resection between 2001 and 2012. Programmed death-ligand-1 (SP142 clone) was applied to the histological sections acquired from the microarray paraffin blocks with immunohistochemistry. Staining intensity was scored as weak (+, 1), moderate (++, 2), and strong (+++, 3). Percentage (0%-100%) was multiplied by staining intensity (1-2-3) to calculate the H score. Four different cut-off values were used; 1: ≥1% (independent of intensity), 2: ≥5% (independent of intensity), 3: ≥5% moderate/strong staining (except for weak staining), 4: H score ≥30 values were considered positive. In this study, staining a single cell at any intensity was considered positive.
Results
Thirty-four out 208 cases (16.3%) had PDL-1 positive staining. PDL-1 expression was observed in patients with non-small cell lung carcinoma independent of the histological type or subtype (range; 0-25%). When the cut-off level was set to ≥5% with moderate and strong staining, the median overall survival was 45 months for the PD-L1 positive group and not reached for the PD-L1 negative group (p-value 0.024). PD-L1 positivity was significantly higher in patients over the age of 60 years and in cases with a tumor diameter of more than 5 cm (p=0.023 and 0.025, respectively).
Conclusion
PD-L1 expression is positive in 16.3% of patients with non-small cell lung cancer and may have a negative prognostic value.
Identifiants
pubmed: 30592196
doi: 10.4274/balkanmedj.galenos.2018.2018.0392
pmc: PMC6528525
doi:
Substances chimiques
Biomarkers, Tumor
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
184-189Références
Oncoimmunology. 2012 Nov 1;1(8):1223-1225
pubmed: 23243584
Sci Rep. 2015 Aug 17;5:13110
pubmed: 26279307
Lung Cancer. 2015 Apr;88(1):24-33
pubmed: 25662388
Eur J Cancer. 2015 Feb;51(3):421-6
pubmed: 25582496
Onco Targets Ther. 2014 Apr 12;7:567-73
pubmed: 24748806
Br J Cancer. 2015 Jan 6;112(1):95-102
pubmed: 25349974
Lab Invest. 2014 Jan;94(1):107-16
pubmed: 24217091
Clin Lung Cancer. 2015 Sep;16(5):385-90
pubmed: 25937270
Lung Cancer. 2015 Aug;89(2):181-8
pubmed: 26024796
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Eur J Cancer. 2015 Nov;51(17):2698-707
pubmed: 26329973
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Ann Oncol. 2014 Oct;25(10):1935-40
pubmed: 25009014
Oncotarget. 2015 Feb 20;6(5):3452-61
pubmed: 25609202
Cancer Immunol Res. 2015 Dec;3(12):1308-15
pubmed: 26546452
Clin Cancer Res. 2004 Aug 1;10(15):5094-100
pubmed: 15297412
PLoS One. 2015 Aug 27;10(8):e0136023
pubmed: 26313362
J Thorac Oncol. 2013 Jun;8(6):803-5
pubmed: 23676558
Oral Oncol. 2015 Mar;51(3):221-8
pubmed: 25500094
Tumori. 2012 Nov;98(6):751-5
pubmed: 23389362
Eur J Cancer. 2016 Apr;57:91-103
pubmed: 26901614
Med Oncol. 2011 Sep;28(3):682-8
pubmed: 20373055
Crit Rev Oncol Hematol. 2016 May;101:75-85
pubmed: 26969107
Medicine (Baltimore). 2015 Feb;94(6):e515
pubmed: 25674748